Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 2, 2014, Pages 463-470

  Wang, Taotao ^a   Chen, Siying ^a   Sun, Jinyue ^a   Cai, Jiangxia ^a   Cheng, Xiaoliang ^b   Dong, Haiyan ^a   Wang, Xue ^a   Xing, Jianfeng ^a   Dong, Weihua ^a   Yao, Hongping ^a   Dong, Yalin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Aspergillus; Candida; NONMEM; Pharmacodynamics; Population pharmacokinetics

Indexed keywords

ALKALINE PHOSPHATASE; CYTOCHROME P450 2C19; VORICONAZOLE;

ADULT; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; OPTIMAL DRUG DOSE; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; SYSTEMIC MYCOSIS; YOUNG ADULT;

ASPERGILLUS; CANDIDA; NONMEM; PHARMACODYNAMICS; POPULATION PHARMACOKINETICS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS, INVASIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MONTE CARLO METHOD; PROSPECTIVE STUDIES; PYRIMIDINES; TRIAZOLES;

EID: 84892470410     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt369     Document Type: Article

References (40)

1. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 45:649-63.
2. Cocchi S, Codeluppi M, Venturelli C et al. Fusarium verticillioides fungemia in a liver transplantation patient: successful treatment with voriconazole. Diagn Microbiol Infect Dis 2011; 71: 438-41.
3. Boyd AE, Modi S, Howard SJ et al. Adverse reactions to voriconazole. Clin Infect Dis 2004; 39: 1241-4.
4. Pascual A, Calandra T, Bolay S et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-11.
5. Pieper S, Kolve H, Gumbinger HG et al. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients. J Antimicrob Chemother 2012; 67: 2717-24.
6. Lee S, Kim B, Nam W et al. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. J Clin Pharmacol 2012; 52: 195-203.
7. Eiden C, Cociglio M, Hillaire-Buys D et al. Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring. Xenobiotica 2010; 40: 701-6.
8. Racil Z, Winterova J, Kouba M et al. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience. Mycoses 2012; 55: 483-92.
9. Weiss J, Ten Hoevel MM, Burhenne J et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol 2009; 49: 196-204.
10. Hamada Y, Seto Y, Yago K et al. Investigation and threshold of optimum blood concentrationof voriconazole:adescriptive statistical meta-analysis. J Infect Chemother 2012; 18: 501-7.
11. Kuti JL, NicolauDP. Making themostof surveillance studies:summaryof the OPTAMA Program. Diagn Microbiol Infect Dis 2005; 53: 281-7.
12. Sun HK, Kuti JL, NicolauDP. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program. Crit Care Med 2005; 33: 2222-7.
13. Andes D, Marchillo K, Stamstad T et al. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in amurine candidiasis model. Antimicrob Agents Chemother 2003; 47: 3165-9.
14. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
15. Pascual A, Csajka C, Buclin T et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis 2012; 55: 381-90.
16. Fernandez de Gatta Mdel M, Santos Buelga D, Sanchez Navarro A et al. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis. Clin Pharmacokinet 2009; 48: 273-80.
17. Mouton JW, Dudley MN, Cars O et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005; 55: 601-7.
18. Masterton RG, Kuti JL, Turner PJ et al. The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe. J Antimicrob Chemother 2005;55: 71-7.
19. Nomura K, Fujimoto Y, Kanbayashi Y et al. Pharmacokineticpharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies. Eur J Clin Microbiol Infect Dis 2008; 27:1141-3.
20. Wahlby U, Thomson AH, Milligan PA et al. Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis. Br J Clin Pharmacol 2004; 58: 367-77.
21. Tan K, Brayshaw N, Tomaszewski K et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006;46: 235-43.
22. Trifilio S, Ortiz R, Pennick G et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005; 35: 509-13.
23. Lombardi LR, Miano TA, Davis JL et al. A retrospective analysis of the effect of patient-specific factors on voriconazole concentrations in oncology patients. J Oncol Pharm Pract 2012; 18: 3-9.
24. Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 2009; 53: 935-44.
25. Mikus G, Scholz I, Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics 2011; 12: 861-72.
26. Goldstein JA. Clinical relevance of genetic polymorphisms in thehuman CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349-55.
27. Berge M, Guillemain R, Tregouet DA et al. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients. Eur J Clin Pharmacol 2011; 67: 253-60.
28. Lat A, Thompson GR 3rd. Update on the optimal use of voriconazole for invasive fungal infections. Infect Drug Resist 2011; 4: 43-53.
29. Dolton MJ, Ray JE, Chen SC et al. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother 2012; 56: 4793-9.
30. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009; 41: 67-76.
31. Mitsani D, Nguyen MH, Shields RK et al. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother 2012; 56: 2371-7.
32. Leveque D, Nivoix Y, Jehl F et al. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 2006; 27: 274-84.
33. Scholz I, Oberwittler H, Riedel KD et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol 2009; 68: 906-15.
34. Han K, Capitano B, Bies R et al. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients. Antimicrob Agents Chemother 2010; 54: 4424-31.
35. Panackal AA, Gribskov JL, Staab JF et al. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 2006;44: 1740-3.
36. Magill SS, Shields C, Sears CL et al. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006; 44: 529-35.
37. Nguyen MH, Yu CY. Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole. J Antimicrob Chemother 1998; 42:253-6.
38. Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother 2011; 55: 4782-8.
39. Lazarus HM, Blumer JL, Yanovich S et al. Safetyand pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 2002; 42: 395-402.
40. Purkins L, Wood N, Ghahramani P et al. Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546-53.